Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Nanobiotix S.A. for the month of May 2026. The filing, dated May 20, 2026, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The company is headquartered in Paris, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release and does not contain a standalone financial statement or tabular data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The specific content of the referenced press release is not included in the input text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the attached Exhibit 99.1, which is not part of the provided text.
Key Facts for Investor Verification
- Verify the full content of the press release dated May 20, 2026 (Exhibit 99.1) to understand the specific announcement triggering this filing.
- Confirm the company's current cash position and runway, as no financial figures are present in this summary document.
- Review the company's Form 20-F for the most recent audited financial statements to assess overall financial health.
- Identify the specific clinical or commercial milestone announced in the press release, as this is the primary purpose of the 6-K.